These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 39096012)

  • 1. Six-minute walk test as outcome measure of fatigability in adults with spinal muscular atrophy treated with nusinersen.
    Govoni A; Ricci G; Bonanno S; Bello L; Magri F; Meneri M; Torri F; Caponnetto C; Passamano L; Grandis M; Trojsi F; Cerri F; Gadaleta G; Capece G; Caumo L; Tanel R; Saccani E; Vacchiano V; Sorarù G; D'Errico E; Tramacere I; Bortolani S; Rolle E; Gellera C; Zanin R; Silvestrini M; Politano L; Schenone A; Previtali SC; Berardinelli A; Turri M; Verriello L; Coccia M; Mantegazza R; Liguori R; Filosto M; Maioli MA; Simone IL; Mongini T; Corti S; Manca ML; Pegoraro E; Siciliano G; Comi GP; Maggi L
    Muscle Nerve; 2024 Oct; 70(4):816-823. PubMed ID: 39096012
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and Treatment Effects of Nusinersen in Longstanding Adult 5q-SMA Type 3 - A Prospective Observational Study.
    Walter MC; Wenninger S; Thiele S; Stauber J; Hiebeler M; Greckl E; Stahl K; Pechmann A; Lochmüller H; Kirschner J; Schoser B
    J Neuromuscul Dis; 2019; 6(4):453-465. PubMed ID: 31594243
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nusinersen for adults with spinal muscular atrophy.
    Arslan D; Inan B; Kilinc M; Bekircan-Kurt CE; Erdem-Ozdamar S; Tan E
    Neurol Sci; 2023 Jul; 44(7):2393-2400. PubMed ID: 36854931
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term nusinersen treatment across a wide spectrum of spinal muscular atrophy severity: a real-world experience.
    Łusakowska A; Wójcik A; Frączek A; Aragon-Gawińska K; Potulska-Chromik A; Baranowski P; Nowak R; Rosiak G; Milczarek K; Konecki D; Gierlak-Wójcicka Z; Burlewicz M; Kostera-Pruszczyk A
    Orphanet J Rare Dis; 2023 Aug; 18(1):230. PubMed ID: 37542300
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nusinersen improves walking distance and reduces fatigue in later-onset spinal muscular atrophy.
    Montes J; Dunaway Young S; Mazzone ES; Pasternak A; Glanzman AM; Finkel RS; Darras BT; Muntoni F; Mercuri E; De Vivo DC; Bishop KM; Schneider E; Bennett CF; Foster R; Farwell W;
    Muscle Nerve; 2019 Oct; 60(4):409-414. PubMed ID: 31298747
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of Nusinersen in Adolescents and Adults with Spinal Muscular Atrophy: Systematic Review and Meta-analysis.
    Hagenacker T; Maggi L; Coratti G; Youn B; Raynaud S; Paradis AD; Mercuri E
    Neurol Ther; 2024 Oct; 13(5):1483-1504. PubMed ID: 39222296
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Six-Minute Walk Test demonstrates motor fatigue in spinal muscular atrophy.
    Montes J; McDermott MP; Martens WB; Dunaway S; Glanzman AM; Riley S; Quigley J; Montgomery MJ; Sproule D; Tawil R; Chung WK; Darras BT; De Vivo DC; Kaufmann P; Finkel RS;
    Neurology; 2010 Mar; 74(10):833-8. PubMed ID: 20211907
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term impact of nusinersen on motor and electrophysiological outcomes in adolescent and adult spinal muscular atrophy: insights from a multicenter retrospective study.
    Wang N; Hu Y; Jiao K; Cheng N; Sun J; Tang J; Song J; Sun C; Wang T; Wang K; Qiao K; Xi J; Zhao C; Yu L; Zhu W
    J Neurol; 2024 Sep; 271(9):6004-6014. PubMed ID: 39030456
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quality of life assessment in adult spinal muscular atrophy patients treated with nusinersen.
    Bonanno S; Zanin R; Bello L; Tramacere I; Bozzoni V; Caumo L; Ferraro M; Bortolani S; Sorarù G; Silvestrini M; Vacchiano V; Turri M; Tanel R; Liguori R; Coccia M; Mantegazza RE; Mongini T; Pegoraro E; Maggi L
    J Neurol; 2022 Jun; 269(6):3264-3275. PubMed ID: 34978620
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nusinersen safety and effects on motor function in adult spinal muscular atrophy type 2 and 3.
    Maggi L; Bello L; Bonanno S; Govoni A; Caponnetto C; Passamano L; Grandis M; Trojsi F; Cerri F; Ferraro M; Bozzoni V; Caumo L; Piras R; Tanel R; Saccani E; Meneri M; Vacchiano V; Ricci G; Soraru' G; D'Errico E; Tramacere I; Bortolani S; Pavesi G; Zanin R; Silvestrini M; Politano L; Schenone A; Previtali SC; Berardinelli A; Turri M; Verriello L; Coccia M; Mantegazza R; Liguori R; Filosto M; Marrosu G; Siciliano G; Simone IL; Mongini T; Comi G; Pegoraro E
    J Neurol Neurosurg Psychiatry; 2020 Nov; 91(11):1166-1174. PubMed ID: 32917822
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Longitudinal Assessment of Timed Function Tests in Ambulatory Individuals with SMA Treated with Nusinersen.
    Krosschell KJ; Brown L; Hoffman K; Zumpf KB; Munson H; Bidwell J; Schulte DP; Schwaede AN; Buehner AN; DiDonato CJ; Kuntz NL; Rao VK
    J Neuromuscul Dis; 2023; 10(3):337-348. PubMed ID: 36872785
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Performance fatigability in adults with spinal muscular atrophy treated long-term with nusinersen.
    Stolte B; Neuhoff S; Lipka J; Schlag M; von Velsen O; Kruse T; Deuschl C; Kleinschnitz C; Hagenacker T
    Muscle Nerve; 2024 Dec; 70(6):1223-1229. PubMed ID: 39360659
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospective Cohort Study of Nusinersen Treatment in Adults with Spinal Muscular Atrophy.
    Yeo CJJ; Simeone SD; Townsend EL; Zhang RZ; Swoboda KJ
    J Neuromuscul Dis; 2020; 7(3):257-268. PubMed ID: 32333595
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Discontinuation of Nusinersen Treatment in Long-Standing SMA3.
    Hiebeler M; Abicht A; Reilich P; Walter MC
    J Neuromuscul Dis; 2021; 8(4):537-542. PubMed ID: 33682724
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fatigue in adults with spinal muscular atrophy under treatment with nusinersen.
    Kizina K; Stolte B; Totzeck A; Bolz S; Schlag M; Ose C; von Velsen O; Kleinschnitz C; Hagenacker T
    Sci Rep; 2020 Jul; 10(1):11069. PubMed ID: 32632203
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of nusinersen in type 1, 2 and 3 spinal muscular atrophy: Real world data from Hungarian patients.
    Szabó L; Gergely A; Jakus R; Fogarasi A; Grosz Z; Molnár MJ; Andor I; Schulcz O; Goschler Á; Medveczky E; Czövek D; Herczegfalvi Á
    Eur J Paediatr Neurol; 2020 Jul; 27():37-42. PubMed ID: 32456992
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 6-minute walk test as a measure of disease progression and fatigability in a cohort of individuals with RYR1-related myopathies.
    Witherspoon JW; Vasavada RP; Waite MR; Shelton M; Chrismer IC; Wakim PG; Jain MS; Bönnemann CG; Meilleur KG
    Orphanet J Rare Dis; 2018 Jul; 13(1):105. PubMed ID: 29970108
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nusinersen in later-onset spinal muscular atrophy: Long-term results from the phase 1/2 studies.
    Darras BT; Chiriboga CA; Iannaccone ST; Swoboda KJ; Montes J; Mignon L; Xia S; Bennett CF; Bishop KM; Shefner JM; Green AM; Sun P; Bhan I; Gheuens S; Schneider E; Farwell W; De Vivo DC;
    Neurology; 2019 May; 92(21):e2492-e2506. PubMed ID: 31019106
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of motor function and nutritional status in children with spinal muscular atrophy treated with nusinersen after loading period in Western China: a retrospective study.
    Yang H; Tao Q; Li D; Yang J; Cai Q; Gan J; Huang S; Luo R
    BMC Neurol; 2023 Jan; 23(1):35. PubMed ID: 36690929
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Later efficacy of nusinersen treatment in adult patients with spinal muscular atrophy: A retrospective case study with a median 4-year follow-up.
    Funato M; Kino A; Iwata R; Yumioka M; Yamashita K; Urui C; Uno R; Kondo E; Morioka E; Ogawa Y; Kawamura A; Kusukawa T; Minatsu H
    Brain Dev; 2024 Jan; 46(1):62-67. PubMed ID: 37657961
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.